EX-12.1 4 y52661exv12w1.htm EX-12.1: COMPUTATION OF RATIOS OF EARNINGS TO FIXED CHARGES EX-12.1
 

         
EXHIBIT 12.1
OSI PHARMACEUTICALS, INC.
RATIOS OF EARNINGS TO FIXED CHARGES (in thousands)
                                         
    Years Ended December 31,     Years Ended September 30,  
    2007     2006     2005     2004 *     2003  
     
Pretax income (loss) from continuing operations
   $ 105,339     $ 6,700     $ (85,094 )   $ (260,371 )   $ (181,357 )
Add:
                                        
Fixed charges
     10,811       11,149       8,909       21,713       10,016  
     
Pretax income (loss) as adjusted
   $ 116,150     $ 17,849     $ (76,185 )   $ (238,658 )   $ (171,341 )
     
 
                                        
Fixed charges:
                                        
Interest, including amortization of debt issuance costs
   $ 9,099     $ 9,201     $ 6,113     $ 18,768     $ 7,549  
Estimated interest portion of rent
     1,712       1,948       2,796       2,945       2,467  
 
                                        
     
Fixed charges
   $ 10,811     $ 11,149     $ 8,909     $ 21,713     $ 10,016  
     
Ratio of earnings to Fixed Charges
     10.7 x     1.6 x     —       —       —  
Deficiency of earnings available to cover fixed charges
     —       —     $ (85,094 )   $ (260,371 )   $ (181,357 )
     
 
    For purposes of calculating earnings to fixed charges, earnings consist of pretax income from continuing operations plus fixed charges. Fixed charges consist of interest expense, amortization of debt issuance cost and an estimate of interest within rental expense.
 
*   Subsequent to the end of our 2004 fiscal year, which ended on September 30, 2004, we changed our fiscal year end to December 31. The deficiency for the three months ended December 31, 2004 was $48.4 million.